DENVER, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Phoenix Life Sciences International Limited (OTCMarkets: MJMD) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that Col. Philip Blair, M.D. has become the Diabetes Director of the company’s Medical Advisory Council.

U.S. Army veteran Dr. Philip Blair is a board-certified family physician who, since starting his company Pro Health Advisor in 2011, has provided innovative disease management by telemedicine to clients in all 50 states. A graduate from West Point and the University of Miami School of Medicine, he has been studying, treating and lecturing about the body’s natural endocannabinoid system (ECS) and the medicine behind cannabis since 2014. Dr. Blair has overseen more than 2,000 patients showing positive results through patient management using medical cannabis extracts.

“We’re very proud and excited to have such a knowledgeable and highly regarded doctor on our Medical Advisory Council,” said Phoenix Life Sciences CEO Martin Tindall. “A leader in diabetes, research, and patient management, we feel Dr. Blair will add great value to our efforts in Vanuatu and our global initiative to treat diabetes in a safe, natural way.”

The Phoenix Life’s Medical Advisory Council is comprised of the top professionals in their respective practice areas and experience in botanical medicine, and more specifically in medical cannabis patient management. Dr. Blair is also an educational speaker who is highly sought after by top medical and cannabis-specific conferences around the world, presenting to audiences ranging from 15 to 500. He’s been involved in research studies involving botanical supplements and medicines in the U.S. and has committed his efforts to exploring alternative treatments for diabetes.

“I believe that Phoenix Life Sciences’ approach to botanical pharmaceuticals has the potential to transform medical care for the Republic of Vanuatu and many other nations,” said Dr. Blair. “I am very excited to work with a company that is dedicated to innovating within the healthcare industry and aims to help those who need it most.”

To learn more about Phoenix Life Sciences International, please visit

About Phoenix Life Sciences International Limited
Phoenix Life Sciences International Limited is an adaptive healthcare solutions company. Our business is to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. We strive to create partnerships and integrate these programs for human health into communities worldwide as part of our Global Health Initiative.


Information contained in this press release regarding Phoenix Life Sciences International, Limited and its subsidiaries, (the “Companies”) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.


These statements have not been evaluated by the FDA and therefore the products sold by Phoenix Life Sciences International are not available on U.S.


Phoenix Life Sciences International does not sell or distribute any products in the United States that are in violation of the United States Controlled Substances Act (US.CSA). This company does not grow, sell, and distribute cannabis-based products in the United States and is solely involved with the legal distribution of medical cannabis-based products within certain international markets outside of the United States.

Investor Contact:

Phone: 1.888.717.5655 or international +1.720.699.7222

Media Contact:

Kathryn Reinhardt
CMW Media